The innovative force behind Ultimovacs’ cancer vaccine Read the article HERE
Other News |
Press Releases
Carlos presenting at BioStock Life Science Fall Summit 2022
Carlos de Sousa, CEO of Ultimovacs, presents the company at BioStock Life Science Fall Summit 2022. BioStock Life Science Summit […]
Anne Worsøe (head of IR) talks about the Ultimovacs journey and our ambitions in this podcast episode (in Norwegian):
Anne Worsøe (Head of IR) talks about the Ultimovacs journey and our ambitions in this podcast episode (in Norwegian): Listen […]
Ultimovacs presentation held at Redeye Investor AW
See Ultimovacs’ Carlos de Sousa (CEO) presenting at Redeye Investor AW – Göteborg 20 October 2022 here
Upcoming events and conferences
An overview of some of the near-term events and conferences where Ultimovacs will participate. Events & Conferences When Where “Meet […]
Career Opportunity: Translational Research Lead – Immune Oncology, permanent position
Location: Oslo (Ullernchausséen 64) About Ultimovacs Ultimovacs is a clinical-stage biotechnology company developing novel immunotherapies against cancer. Our lead product […]
Interview with Carlos – ABGSC Investor Days 8 mars 2022
Enter the interview here
Biostock Article: Wave of positive momentum in 2022
Ultimovacs to ride wave of positive momentum in 2022 Ultimovacs’ Q4 report has been released and it reflects the company’s […]
Biostock article: Ultimovacs progresses to last cohort in TENDU study
“Ultimovacs continues to progress with its phase I TENDU study testing the company’s TET cancer vaccine platform in prostate cancer […]
Presentation at Redeye Fight Cancer
On January 20th, our CEO Carlos de Sousa participated at Redeye #FightCancer Outlook 2022 with some of the leading #Nordicbiotech […]